Aeterna
Zentaris announced earlier today the recruitment of Richard Sachse, MD, PhD, to
the position of Senior Vice President, Chief Scientific Officer. Prior to
joining Aeterna Zentaris, Dr. Sachse sat as Vice President, Head of Global
Translational Medicine, at Boehringer Ingelheim.
“We
are very proud to welcome Dr. Sachse to our leadership team. As CSO, he will be
responsible for all areas of our global research and development activities,
while also serving on the corporate Operating Committee. In developing his
industry career, Dr. Sachse has held increasingly responsible positions with
several leading pharmaceutical companies, including Bayer, Schwarz Pharma, UCB
and Boehringer Ingelheim, overseeing major drug development programs in a
variety of different therapeutic areas, including oncology and endocrinology,”
stated President and CEO of Aeterna Zentaris, David Dodd.
Dr.
Sachse commented in response, “I am delighted to get the opportunity to become
part of Aeterna Zentaris’ team and very much looking forward to contribute in
advancing the Company’s portfolio pipeline along the value chain. I believe
that the combination of Aeterna Zentaris’ highly qualified and motivated
personnel, together with its strong scientific platform, holds much promise for
the future success of our projects.”
Dr.
Sachse earned a degree in medicine from the Friedrich-Alexander-University
Erlangen in Germany, as well as board certification in Clinical Pharmacology.
With over 20 years of experience as a physician and scientist, he holds
extensive expertise in a variety of different therapeutic areas, including
oncology and endocrinology. In addition to registration studies, he is
specifically experienced in the design and implementation of translational
programs to bridge research programs to the clinic, as well as in the design
and implementation of clinical pharmacology programs, including all required
profiling studies and activities which enable successful registration of
products at an international level.
From
1996 to 2000, Dr. Sachse held the role of International Project Leader at the
Bayer AG Institute for Clinical Pharmacology, and Principal Investigator at the
Bayer Clinical Pharmacology Unit. While there he implemented innovative
exploratory development tools, including biomarkers, which are used to
demonstrate early Proof of Concept. From 2001 to 2006, he held a number of
different management roles within early and late phase clinical development
programs, including responsibilities for completed Phase 3 programs leading to
successful NDA/MAA submissions. In 2007, he became Senior Director, Head of
Experimental Medicine, at UCB in Belgium after a merger. It was here that he
managed the implementation of novel biomarkers in clinical development in order
to provide data supporting identification of appropriate target indication and
target population.
For
more information, please visit www.aezsinc.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
